Effectiveness of LORlatinib as a Real-World, first-line treatment in ALK-positive Advanced Non-Small Cell Lung Cancer Patients in Germany. (LOR-ALK). First published 26/06/2026 Last updated 26/06/2026 EU PAS number:EUPAS1000000583 Study Planned